FILSPARI Gains EU Approval for IgA Nephropathy Treatment
April 29, 2025
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) CSL Vifor and Travere Therapeutics, Inc. are